2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 11, 2015

11:00AM-12:30PM: Abstract Number: 3258

Different Perception of Disease Activity in Multimorbid Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects VII: Disease Activity and Updates in Measurement

11:00AM-12:30PM: Abstract Number: 3256

Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Clinical Aspects VII: Disease Activity and Updates in Measurement

11:00AM-12:30PM: Abstract Number: 3261

Examining the Impact of Radiation Therapy on Scleroderma and Cancer Outcomes in Scleroderma Patients with Breast Cancer

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3268

Foot and Ankle Characteristics Associated with Falls in People with Rheumatoid Arthritis: A Prospective Longitudinal Study

ARHP VI: Physical Function and Disability

11:00AM-12:30PM: Abstract Number: 3267

Functional Disability in Adolescents Is Predicted By Self-Report of Sleep Problems, Depressive Symptoms, Low Physical Activity and Worst Pain Intensity Levels

ARHP VI: Physical Function and Disability

11:00AM-12:30PM: Abstract Number: 3259

Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3252

Impact of Knee Pain Frequency on Physical Function in the Osteoarthritis Initiative

Pain: Clinical Aspects

11:00AM-12:30PM: Abstract Number: 3260

Increased Frequency of Malignancies Synchronous to the Onset of Systemic Sclerosis in Anti-RNA Polymerase III Antibodies Positive Patients: A Eustar Multicentre Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3266

Keeping Baby Boomers in the Labour Force Longer: What Does It Mean for Workers with Arthritis?

ARHP VI: Physical Function and Disability

11:00AM-12:30PM: Abstract Number: 3264

Multiplex Serum Protein Analysis in Systemic Sclerosis Defines Potential Anti-Fibrotic Mechanisms and Markers of Response to Hyperimmune Caprine Serum

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3249

Pooled Efficacy and Safety from Phase 3 Controlled Studies of Tanezumab in Patients with Osteoarthritis

Pain: Clinical Aspects

11:00AM-12:30PM: Abstract Number: 3265

Sustaining Employment with Arthritis: Can Existing Workplace Policies and Accommodations Make a Difference?

ARHP VI: Physical Function and Disability

11:00AM-12:30PM: Abstract Number: 3250

Systemic Inflammation and Pain Sensitization in Knee Osteoarthritis: The Multicenter Osteoarthritis Study

Pain: Clinical Aspects

11:00AM-12:30PM: Abstract Number: 3262

The Influence of Immunosuppressive Therapy on Microangiopathy in Systemic Sclerosis As Measured with Nailfoldcapillaroscopy

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 3257

The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors

Rheumatoid Arthritis - Clinical Aspects VII: Disease Activity and Updates in Measurement

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].